Indication
Myxoid Round Cell Liposarcoma
1 clinical trial
2 products
Product
MAGE-A4ᶜ¹º³²T cellsClinical trial
Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4ᶜ¹º³²T in HLA-A2+ Subjects With MAGE-A4 Positive TumorsStatus: Active (not recruiting), Estimated PCD: 2022-12-27